Spectris plc has a fifty-two week low of GBX 2,370 ($29.29) and a fifty-two week high of GBX 3,730 ($46.09). The company has a debt-to-equity ratio of 4.37, a current ratio of 2.36 and a quick ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

JPMorgan upgraded Spectris Plc (LON:SXS:LN) (OTC: SEPJF) stock from Neutral to Overweight, increasing the price target to GBP34.50, up from the previous GBP26.50. The adjustment reflects a positive ...

The study, titled “CSF Proteomics Reveals Changes in Myelin and Synaptic Biology Following Spectris™ Treatment,” offers compelling evidence of Spectris™’ ability to modulate core ...

CAMBRIDGE, Mass., February 11, 2025--(BUSINESS WIRE)--Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, today announced the publication ...

The study, titled “CSF Proteomics Reveals Changes in Myelin and Synaptic Biology Following Spectris™ Treatment,” offers compelling evidence of Spectris™’ ability to modulate core biological pathways ...

JPMorgan Cazenove upgraded Spectris on Monday to 'overweight' from 'neutral' and hiked the price target to 3,450.0p from 2,650.0p. The bank said its analysis points to key end markets now ...

JPMorgan Cazenove upgraded Spectris on Monday to ‘overweight’ from ‘neutral’ and hiked the price target to 3,450p from 2,650p. The bank said its analysis points to key end markets now ...